QT interval prolongation and arrhythmia: an unbreakable connection?
1Department of Cardiovascular Medicine, Vanderbilt University Medical School, Nashville, TN, USA. mark.anderson@vanderbilt.edu
Insights
QT interval prolongation can increase arrhythmia risk, yet also serve as an antiarrhythmic strategy. Calmodulin kinase II (CaMKII) activation downstream of QT prolongation contributes to proarrhythmia, suggesting CaMKII inhibition as a therapeutic target.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- QT interval prolongation is linked to arrhythmia risk but also used therapeutically.
- The precise cellular mechanisms underlying QT prolongation's proarrhythmic effects remain incompletely understood.
Purpose of the Study:
- To investigate the role of calmodulin kinase II (CaMKII) in the proarrhythmic consequences of QT interval prolongation.
- To explore CaMKII as a potential therapeutic target for managing arrhythmias associated with QT prolongation.
Main Methods:
- Cellular electrophysiology studies examining action potential duration and Ca2+ signaling.
- In vivo arrhythmia models to assess the impact of CaMKII inhibition.
Main Results:
- QT interval prolongation activates CaMKII, a specific cellular proarrhythmic signal.
- Inhibition of CaMKII prevents arrhythmia surrogates and in vivo arrhythmias linked to excessive action potential prolongation.
Conclusions:
- QT interval prolongation alone does not fully explain proarrhythmia; CaMKII activation is a key downstream mediator.
- CaMKII plays a significant role in the proarrhythmic effects of excessive QT prolongation, indicating its potential as a therapeutic target.
Abstract:
QT interval prolongation is incontrovertibly linked to increased risk of arrhythmias but, paradoxically, QT interval prolongation can also be an effective antiarrhythmic strategy and is in fact the goal of class III antiarrhythmic drugs. This discussion examines the cellular effects of QT interval prolongation and proposes that calmodulin kinase II (CaMKII) is a specific cellular proarrhythmic signal that is activated downstream to QT interval prolongation. Inhibition of CaMKII can prevent cellular arrhythmia surrogates and in vivo arrhythmias linked to excessive action potential prolongation, suggesting that QT interval prolongation alone does not fully account for proarrhythmia. This reasoning points to the conclusion that QT interval modulation and prolongation not only grades cellular Ca2+ entry for cardiac contraction but also has the potential to recruit Ca2+-activated signalling molecules. CaMKII is one of these molecules and CaMKII activity is at least partially responsible for the proarrhythmic consequences of excessive QT interval prolongation.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias II: Classification of Tachyarrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias


